Overview: Acylcarnitine C6 TestIntroduction: The Acylcarnitine C6 Test detects Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), which can cause sudden low blood sugar or seizures during fasting or illness, especially in children, aiding in early management. Affecting 1 in 15,000 newborns in Northern European populations, MCAD poses a diagnostic challenge during asymptomatic periods, with risks escalating during viral infections or prolonged fasting. Following 2023 ACMG guidelines, it uses tandem mass spectrometry (MS/MS) for high specificity, supporting metabolic screening. This test is vital for diagnosis, treatment planning, and improving outcomes in biochemistry, aiming to prevent sudden death.
Other Names: C6 Assay, Hexanoylcarnitine Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for precision.
Historical Milestone: Acylcarnitine testing began in the 1990s with newborn screening by Dietrich Matern, focusing on fatty acid oxidation defects. Tandem MS advancements in the 2000s by Waters Corporation enhanced detection of C6 carnitine, surpassing earlier liquid chromatography-mass spectrometry (LC-MS) methods that lacked sensitivity for rare metabolic disorders.
Purpose: Measures C6 acylcarnitine levels to diagnose MCAD Deficiency, guides dietary management with cornstarch and medium-chain triglycerides, and evaluates children with hypoglycemia or seizures, aiming to avoid metabolic crises during illness or fasting that could lead to coma.
Test Parameters: C6 acylcarnitine levels
Pretest Condition: Fasting preferred for 6-8 hours to assess baseline metabolism and detect abnormalities. Collect dried blood spot, plasma, or serum. Report history of hypoglycemia, seizures, or recent infections.
Specimen: Dried Blood Spot (filter paper, 3-5 spots), Plasma (NaHep, 2-4 mL), Serum (SST, 2-5 mL); 2 mL plasma in Na Heparin tube or dried blood spot on filter paper. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document hypoglycemia, seizures, or illness history. Include dietary habits, exercise patterns, or family history of metabolic disorders, noting any recent fasting or viral exposure that could trigger symptoms.
Consent: Written consent required, detailing the test's purpose, MCAD risks (e.g., sudden death, rhabdomyolysis), and potential risks of sample collection, emphasizing neonatal screening benefits and long-term management plans.
Procedural Considerations: Uses tandem mass spectrometry (MS/MS) to measure C6 levels, requiring laboratories with Waters Xevo TQ-S systems and trained technicians to handle dried blood spots. Results are available in 2-3 days, supporting pediatric care. Performed in labs with sample drying protocols and humidity control to prevent degradation and ensure accurate metabolite detection.
Factors Affecting Result Accuracy: Improper drying, contamination with skin oils, or exposure to heat can affect results. Fasting status, medications, or concurrent illness may alter levels, necessitating controlled conditions and clinical correlation to avoid misdiagnosis.
Clinical Significance: Elevated C6 confirms MCAD Deficiency, guiding carnitine and cornstarch therapy to maintain blood glucose levels. A child with early treatment might prevent hypoglycemic seizures, while untreated cases can lead to sudden cardiac arrest or developmental delays. Normal levels may require genetic testing (e.g., ACADM) to rule out carriers or alternative diagnoses.
Specialist Consultation: Consult a metabolic specialist or pediatrician for result interpretation and management, particularly for infants or those with family history, where dietary adjustments and emergency plans are critical to prevent crises.
Additional Supporting Tests: Urine organic acids, ACADM gene analysis, or acylcarnitine profile to confirm diagnosis and assess enzyme activity, aiding in personalized care and monitoring long-term outcomes.
Test Limitations: Non-specific for severity; clinical correlation with symptoms and genetics is needed. Sensitivity varies with age and fasting state, requiring repeat testing during illness or symptomatic periods.
References: ACMG Guidelines, 2023; Journal of Pediatrics, Wilcken B, 2022.
